Spyre Therapeutics, Inc. (SYRE) Financial Statements
Industry: Pharmaceutical Preparations
In fiscal 2025, Spyre Therapeutics reported revenue of $0. Net income was -$155.2M, or -$1.98 per diluted share. Operating activities generated -$169.3M of cash. At fiscal year end, Spyre Therapeutics held $777.8M in total assets against $62.5M in total liabilities, including $85.7M of cash and equivalents.
Open the full interactive Spyre Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Spyre Therapeutics Key Stats
| Share Price | $80.45 |
|---|---|
| Market Cap | $6.82B |
| 52-Week Range | $18.92 – $108.92 |
| Shares Outstanding | 84.7 million (basic, 2026 Q2) |
Spyre Therapeutics Income Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $18.7M | $2.3M | $886,000 | $0 | $0 |
| Operating Income | -$81.5M | -$65.6M | -$84.8M | -$242.3M | -$208.6M | -$209.6M |
| Pre-Tax Income | -$80.9M | -$65.7M | -$84.0M | -$338.8M | -$208.0M | -$155.2M |
| Income Tax | $0 | $141,000 | -$136,000 | -$26,000 | $51,000 | -$15,000 |
| Net Income | -$80.9M | -$65.8M | -$83.8M | -$338.8M | -$208.0M | -$155.2M |
| Diluted EPS | -$38.00 | -$25.00 | -$24.75 | -$49.12 | -$3.18 | -$1.98 |
Spyre Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$11.2M | -$62.5M | -$69.0M | -$36.2M |
| Diluted EPS | -$0.15 | -$0.98 | -$0.74 | -$0.36 |
Spyre Therapeutics Balance Sheet
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $90.1M | $15.1M | $34.9M | $188.9M | $89.4M | $85.7M |
| Current Assets | $149.8M | $98.9M | $62.3M | $341.5M | $608.5M | $777.8M |
| Total Assets | $161.6M | $109.9M | $71.1M | $341.9M | $608.5M | $777.8M |
| Current Liabilities | $16.4M | $20.1M | $14.7M | $32.0M | $54.1M | $58.7M |
| Total Liabilities | $21.8M | $26.0M | $20.8M | $73.3M | $90.7M | $62.5M |
| Shareholders' Equity | $139.8M | $83.9M | $50.3M | $184.0M | $517.8M | $715.2M |
Spyre Therapeutics Cash Flow Statement
| FY 2020 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$75.8M | -$53.7M | -$80.1M | -$99.9M | -$157.4M | -$169.3M |
| Cash From Investing | -$7.6M | -$22.6M | $57.0M | -$108.4M | -$353.3M | -$143.5M |
| Cash From Financing | $154.5M | $1.4M | $42.7M | $361.1M | $410.9M | $309.0M |
| Free Cash Flow | -$80.1M | -$54.3M | -$80.2M | -$99.9M | -$157.4M | — |
Figures from Spyre Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Spyre Therapeutics financials page for every line item.
Spyre Therapeutics Company Profile
| Ticker | SYRE |
|---|---|
| Exchange | Nasdaq |
| Industry | Pharmaceutical Preparations |
| Headquarters | Waltham, Massachusetts |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Large accelerated filer |
| SEC CIK | 0001636282 |
Frequently Asked Questions
What was Spyre Therapeutics' revenue in fiscal 2025?
Spyre Therapeutics (SYRE) reported revenue of $0 for fiscal 2025.
What is Spyre Therapeutics' annual revenue history?
Spyre Therapeutics' annual revenue by fiscal year: 2020: $0; 2021: $18.7M; 2022: $2.3M; 2023: $886,000; 2024: $0; 2025: $0.
What was Spyre Therapeutics' net income in fiscal 2025?
Spyre Therapeutics reported net income of -$155.2M for fiscal 2025.
What was Spyre Therapeutics' earnings per share (EPS) in fiscal 2025?
Spyre Therapeutics' diluted EPS was -$1.98 for fiscal 2025 (adjusted for any later stock splits).
What was Spyre Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Spyre Therapeutics reported revenue of $0.
How many shares of Spyre Therapeutics are outstanding?
Spyre Therapeutics reported a weighted average of 84.7 million basic shares outstanding in 2026 Q2.
What is Spyre Therapeutics' market cap?
Based on its latest closing price, Spyre Therapeutics (SYRE) has a market capitalization of about $6.82B.
When does Spyre Therapeutics' fiscal year end?
Spyre Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Spyre Therapeutics headquartered?
Spyre Therapeutics lists its business address in Waltham, Massachusetts in its SEC filings.